세계의 제네릭 주사제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2033년)

Global Generic Injectables Market is poised to witness substantial growth, reaching a value of USD 415.81 Billion by the year 2033, up from USD 140.19 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 12.84% between 2025 and 2033.

The global generic injectables market is witnessing robust growth driven by increasing demand for cost-effective and accessible injectable medications across therapeutic areas such as oncology, anti-infectives, and cardiovascular diseases. The rising prevalence of chronic and acute conditions, coupled with patent expirations of branded injectables, is expanding the generic injectables segment. Advances in formulation technologies, including lyophilization and prefilled syringes, are enhancing product stability, safety, and patient compliance. Regulatory frameworks promoting biosimilar and generic drug approvals are facilitating market entry and competition.

The growing adoption of hospital and outpatient injectable therapies, especially in emerging markets, is fueling demand. Manufacturing innovations focusing on sterile production, quality control, and supply chain optimization are improving product availability and affordability. Additionally, the COVID-19 pandemic has underscored the importance of injectable therapeutics, accelerating market growth. Strategic partnerships between pharmaceutical companies and contract manufacturing organizations (CMOs) are enhancing capacity and innovation.

As healthcare systems emphasize cost containment and expanded access, the generic injectables market is poised for sustained expansion, delivering affordable and high-quality injectable therapies globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Generic Injectables market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

• Large Molecule Injectables
• Small Molecule Injectables

By Application

• Oncology
• Infectious Diseases
• Cardiology
• Diabetes
• Immunology
• Others

By Container Type

• Vials
• Premix
• Prefilled Syringes
• Ampoules
• Others

By Route of Administration

• Intravenous
• Intramuscular
• Subcutaneous
• Others
• List of Companies Profiled in the report
• AstraZeneca, Baxter International Inc., Biocon, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Lupin Ltd., Merck KGaA, Mylan N.V., Novartis AG (Sandoz International GmbH), Pfizer Inc., Piramal Pharma Solutions, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. GENERIC INJECTABLES - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product Type
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By Container Type
  • 3.7.4 Market Attractiveness Analysis By Route of Administration
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GENERIC INJECTABLES MARKET ANALYSIS BY PRODUCT TYPE

• 5.1. Overview By Product Type
• 5.2. Historical and Forecast Data Analysis By Product Type
• 5.3. Large Molecule Injectables Historic and Forecast Sales By Regions
• 5.4. Small Molecule Injectables Historic and Forecast Sales By Regions

6. GLOBAL GENERIC INJECTABLES MARKET ANALYSIS BY APPLICATION

• 6.1. Overview By Application
• 6.2. Historical and Forecast Data Analysis By Application
• 6.3. Oncology Historic and Forecast Sales By Regions
• 6.4. Infectious Diseases Historic and Forecast Sales By Regions
• 6.5. Cardiology Historic and Forecast Sales By Regions
• 6.6. Diabetes Historic and Forecast Sales By Regions
• 6.7. Immunology Historic and Forecast Sales By Regions
• 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL GENERIC INJECTABLES MARKET ANALYSIS BY CONTAINER TYPE

• 7.1. Overview By Container Type
• 7.2. Historical and Forecast Data Analysis By Container Type
• 7.3. Vials Historic and Forecast Sales By Regions
• 7.4. Premix Historic and Forecast Sales By Regions
• 7.5. Prefilled Syringes Historic and Forecast Sales By Regions
• 7.6. Ampoules Historic and Forecast Sales By Regions
• 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL GENERIC INJECTABLES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 8.1. Overview By Route of Administration
• 8.2. Historical and Forecast Data Analysis By Route of Administration
• 8.3. Intravenous Historic and Forecast Sales By Regions
• 8.4. Intramuscular Historic and Forecast Sales By Regions
• 8.5. Subcutaneous Historic and Forecast Sales By Regions
• 8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL GENERIC INJECTABLES MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE GENERIC INJECTABLES COMPANIES

• 10.1. Generic Injectables Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF GENERIC INJECTABLES INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. AstraZeneca
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Baxter International Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Biocon
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Fresenius SE & Co. KGaA
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. GlaxoSmithKline Plc
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Hikma Pharmaceuticals Plc
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Johnson & Johnson Services Inc.
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Lupin Ltd.
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Merck KGaA
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Mylan N.V.
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Novartis AG (Sandoz International GmbH)
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Pfizer Inc.
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments
• 11.15. Piramal Pharma Solutions
  • 11.15.1 Company Overview
  • 11.15.2 Company Revenue
  • 11.15.3 Products
  • 11.15.4 Recent Developments
• 11.16. Sun Pharmaceutical Industries Ltd.
  • 11.16.1 Company Overview
  • 11.16.2 Company Revenue
  • 11.16.3 Products
  • 11.16.4 Recent Developments
• 11.17. And Teva Pharmaceutical Industries Ltd
  • 11.17.1 Company Overview
  • 11.17.2 Company Revenue
  • 11.17.3 Products
  • 11.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies